During the past decade, Dublin Hematology Oncology Care PC conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 7 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dublin Hematology Oncology Care PC" #1 sponsor was "National Cancer Institute (NCI)" with 5 trials, followed by "Alliance for Clinical Trials in Oncology" with 1 trials sponsored, "GTx" with 1 trials sponsored, "Millennium Pharmaceuticals, Inc." with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dublin Hematology Oncology Care PC" #1 collaborator was "Aptuit" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "NRG Oncology" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "SWOG Cancer Research Network" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Dublin Hematology Oncology Care PC" are "Recurrent Breast Carcinoma" (3 trials), "HER2/Neu Positive" (2 trials), "Invasive Breast Carcinoma" (2 trials), "Progesterone Receptor Positive" (2 trials) and "Stage IV Breast Cancer AJCC v6 and v7" (2 trials). Many other conditions were trialed in "Dublin Hematology Oncology Care PC" in a lesser frequency.

Most popular intervention types in "Dublin Hematology Oncology Care PC" are "Drug" (9 trials), "Other" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (5 trials), "Paclitaxel" (3 trials), "Quality-of-Life Assessment" (3 trials), "Bevacizumab" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Dublin Hematology Oncology Care PC" are 5 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Dublin Hematology Oncology Care PC". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Dublin Hematology Oncology Care PC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dublin Hematology Oncology Care PC, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".